Dr. Reddy’s Laboratories Ltd ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $68.56
- Today's High:
- $69.23
- Open Price:
- $68.56
- 52W Low:
- $49.0562
- 52W High:
- $73.17
- Prev. Close:
- $68.28
- Volume:
- 237436
Company Statistics
- Market Cap.:
- $11.36 billion
- Book Value:
- 246.4259
- Revenue TTM:
- $261.11 billion
- Operating Margin TTM:
- 23.57%
- Gross Profit TTM:
- $113.84 billion
- Profit Margin:
- 18.08%
- Return on Assets TTM:
- 12.19%
- Return on Equity TTM:
- 21.19%
Company Profile
Dr. Reddy’s Laboratories Ltd ADR had its IPO on 2001-04-11 under the ticker symbol RDY.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Dr. Reddy’s Laboratories Ltd ADR has a staff strength of 25,863 employees.
Stock update
Shares of Dr. Reddy’s Laboratories Ltd ADR opened at $68.56 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $68.56 - $69.23, and closed at $68.84.
This is a +0.82% increase from the previous day's closing price.
A total volume of 237,436 shares were traded at the close of the day’s session.
In the last one week, shares of Dr. Reddy’s Laboratories Ltd ADR have increased by +1.18%.
Dr. Reddy’s Laboratories Ltd ADR's Key Ratios
Dr. Reddy’s Laboratories Ltd ADR has a market cap of $11.36 billion, indicating a price to book ratio of 3.6523 and a price to sales ratio of 0.039.
In the last 12-months Dr. Reddy’s Laboratories Ltd ADR’s revenue was $261.11 billion with a gross profit of $113.84 billion and an EBITDA of $73.82 billion. The EBITDA ratio measures Dr. Reddy’s Laboratories Ltd ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Dr. Reddy’s Laboratories Ltd ADR’s operating margin was 23.57% while its return on assets stood at 12.19% with a return of equity of 21.19%.
In Q2, Dr. Reddy’s Laboratories Ltd ADR’s quarterly earnings growth was a positive 18% while revenue growth was a positive 29.2%.
Dr. Reddy’s Laboratories Ltd ADR’s PE and PEG Ratio
- Forward PE
- 20.7039
- Trailing PE
- 19.9067
- PEG
- 1.5199
Its diluted EPS in the last 12-months stands at $3.43 per share while it has a forward price to earnings multiple of 20.7039 and a PEG multiple of 1.5199. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Dr. Reddy’s Laboratories Ltd ADR’s profitability.
Dr. Reddy’s Laboratories Ltd ADR stock is trading at a EV to sales ratio of 0.0401 and a EV to EBITDA ratio of 0.1586. Its price to sales ratio in the trailing 12-months stood at 0.039.
Dr. Reddy’s Laboratories Ltd ADR stock pays annual dividends of $40 per share, indicating a yield of 0.71% and a payout ratio of 28.05%.
Balance sheet and cash flow metrics
- Total Assets
- $335.04 billion
- Total Liabilities
- $55.36 billion
- Operating Cash Flow
- $0
- Capital Expenditure
- $12.17 billion
- Dividend Payout Ratio
- 28.05%
Dr. Reddy’s Laboratories Ltd ADR ended 2024 with $335.04 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $335.04 billion while shareholder equity stood at $245.26 billion.
Dr. Reddy’s Laboratories Ltd ADR ended 2024 with $0 in deferred long-term liabilities, $55.36 billion in other current liabilities, 833000000.00 in common stock, $230.02 billion in retained earnings and $4.24 billion in goodwill. Its cash balance stood at $6.02 billion and cash and short-term investments were $61.16 billion. The company’s total short-term debt was $7,590,000,000 while long-term debt stood at $3.80 billion.
Dr. Reddy’s Laboratories Ltd ADR’s total current assets stands at $113.56 billion while long-term investments were $4.90 billion and short-term investments were $53.03 billion. Its net receivables were $77.25 billion compared to accounts payable of $55.36 billion and inventory worth $52.40 billion.
In 2024, Dr. Reddy’s Laboratories Ltd ADR's operating cash flow was $0 while its capital expenditure stood at $12.17 billion.
Comparatively, Dr. Reddy’s Laboratories Ltd ADR paid $0.28 in dividends in 2024.
Other key metrics
- Current Trading Price
- $68.84
- 52-Week High
- $73.17
- 52-Week Low
- $49.0562
- Analyst Target Price
- $69.61
Dr. Reddy’s Laboratories Ltd ADR stock is currently trading at $68.84 per share. It touched a 52-week high of $73.17 and a 52-week low of $73.17. Analysts tracking the stock have a 12-month average target price of $69.61.
Its 50-day moving average was $67.45 and 200-day moving average was $58.06 The short ratio stood at 6.21 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 1202% are held by institutions.
Frequently Asked Questions About Dr. Reddy’s Laboratories Ltd ADR
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy’s Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.